Description:

GYNECOLOGIC ONCOLOGY GROUP Follow-Up Form - FORM Q NCT00565851 Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DA625200-CCA6-1B50-E034-0003BA12F5E7

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DA625200-CCA6-1B50-E034-0003BA12F5E7

Keywords:
Versions (4) ▾
  1. 9/19/12
  2. 1/9/15
  3. 1/9/15
  4. 7/3/15
Uploaded on:

July 3, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

GYNECOLOGIC ONCOLOGY GROUP Follow-Up Form - FORM Q NCT00565851

No Instruction available.

  1. StudyEvent: GYNECOLOGIC ONCOLOGY GROUP Follow-Up Form - FORM Q
    1. No Instruction available.
Header module
Vital Status
Patient's vital status
Primary cause of death:
Is the patient lost to follow-up?
Notice Of Progression
Has the patient been diagnosed with a new progression?
What was the method used to determine progression?
Ca125 And Other Biomarkers
Notice Of New Primary
Has a new primary cancer or MDS been diagnosed that has not been previously reported? (myelodysplastic syndrome)
Late Adverse Event
Has the patient experienced (prior to diagnosis of recurrence or second primary) any severe (Grade >=3), long term toxicity that has not been previously reported?
CTC adverse event attribution code (*)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer therapy not previously reported?
Comments

Similar models